Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. - Wikidata - wikimedia - TriplyDB

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

http://www.wikidata.org/entity/Q33891844

about

Subfunctionalization of duplicated zebrafish pax6 genes by cis-regulatory divergence Asymmetrical distribution of non-conserved regulatory sequences at PHOX2B is reflected at the ENCODE loci and illuminates a possible genome-wide trend Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function Control of the SOST bone enhancer by PTH using MEF2 transcription factors Pathogenesis of osteoporosis: concepts, conflicts, and prospects Wnt modulators in the biotech pipeline Effects of PTH on osteocyte function Sclerostin Inhibition in the Management of Osteoporosis Decoding the non-coding genome: elucidating genetic risk outside the coding genome The complexity of epigenetic diseases Catabolic and anabolic actions of parathyroid hormone on the skeleton Variation in vertebrate cis-regulatory elements in evolution and disease Beyond the zebrafish: diverse fish species for modeling human disease In vitro and in vivo approaches to study osteocyte biology Using the ENCODE Resource for Functional Annotation of Genetic Variants Control of bone mass and remodeling by PTH receptor signaling in osteocytes Discovery and characterization of human exonic transcriptional regulatory elements Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody Genetic evidence that SOST inhibits WNT signaling in the limb Conserved noncoding elements follow power-law-like distributions in several genomes as a result of genome dynamics.Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone.iSVP: an integrated structural variant calling pipeline from high-throughput sequencing data Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway Evolution of conserved secondary structures and their function in transcriptional regulation networks Nuclear alpha NAC influences bone matrix mineralization and osteoblast maturation in vivo Profile of romosozumab and its potential in the management of osteoporosis.Parathyroid hormone: anabolic and catabolic actions on the skeleton Evolutionary mutant models for human disease Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis A systematic enhancer screen using lentivector transgenesis identifies conserved and non-conserved functional elements at the Olig1 and Olig2 locus.Update in new anabolic therapies for osteoporosis Wnts' fashion statement: from body stature to dysplasia.Bone mass is inversely proportional to Dkk1 levels in mice.Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts Genomic identification of regulatory elements by evolutionary sequence comparison and functional analysis Genomic features and computational identification of human microRNAs under long-range developmental regulation Sclerostin: current knowledge and future perspectives.SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease.

P2860

Q21145050-DF6D3982-DF0F-4049-820B-F861B72CEA5B Q21267236-4708A65D-3B66-47F9-B1FC-F76D717F48FE Q21560844-82FEDC5C-DBBF-41FE-9E10-F44AAC7EBA0C Q24299076-136C31E9-F0CF-4F2D-A431-EEA366676CE7 Q24337339-7E118F39-D100-414A-8DAC-4D3D49CBD3F9 Q24536164-8CEB086A-35D3-4353-B052-4B59E797FF4C Q24618567-6FC35D11-8EA8-451E-B423-B894BC9D5815 Q24631082-2E9FB076-D791-454F-B524-BFC4A0B6C9C5 Q26750713-B6683DB6-ABB0-4814-BF5C-CC06B3F5C3D2 Q26777924-4BBA3488-A764-4CA2-9055-F6FADCC07ED8 Q26784416-8072F5D0-F88F-4769-81E7-6BBED7358B5C Q26828873-2773D800-8953-4058-AEDD-9EB50D727F00 Q26851780-506AE191-167E-4922-A181-0CCBB7ACF8A4 Q26853001-CC3D3E6E-F24D-4A4B-B2A5-AE3E06940529 Q26858876-55C59539-D863-4B96-B9C1-ED731A2392B2 Q26865379-1DD5A356-C78C-41D5-8CDF-94684AE2C036 Q27300741-09F0E34E-106D-4673-A350-B69A09FAC5CD Q28276197-B420F60D-DB1D-4D48-ACD6-0B6F9DE12055 Q28286616-EF90FAAB-57A4-413A-B8B8-F5DF31742938 Q28509512-8ACEA1EE-7E2D-4B82-9078-E3A73504FC87 Q30577485-9155220E-16BA-4117-AF92-1E3EACCCAE8F Q30619950-B5208AC2-2A64-4F88-A72B-C09DD90788A3 Q30763394-63DC5C0B-D99F-4A34-BA9B-9EE034B1EAC0 Q30914003-AB5B791D-3361-4F60-840C-EABE12B63416 Q31032805-E6B47665-122E-4E17-924C-2C2F35172CD9 Q33381889-097B01DB-E048-4822-BD5B-898DDFE0BA73 Q33558145-C9B1EE8F-EB71-4961-B43B-2D999EB29759 Q33596475-8A3D3433-A503-497F-AA30-2DB034D9D853 Q33609126-DC24C91D-5CDF-41BC-862F-F2E58E33FFF0 Q33686021-31474304-5C1C-48DF-A01C-48A36BE4AD74 Q33695718-E9CB6CE4-5F5C-413A-8246-0203D845B45B Q33785737-8671C161-456B-4383-BC63-1B6DB8CD74F2 Q33786824-92CA15E0-3B3C-485A-A101-11CE24225ABA Q33833409-6BE9AE0F-ECBE-4F06-A418-85A9A2C3FDF0 Q33834902-A6855B1A-80C8-4258-A945-ACFA116CDA7B Q33895465-5DCA1B7A-0F12-428A-97AE-DF01F3C53F5E Q33899702-97856530-3AC4-461C-BF03-8D434EFAA773 Q33914388-EA4CAE1A-E025-4BFF-BAEB-2A26D6636A9C Q33992612-CC9C4A9A-72B1-428E-B7EB-19660600E29A Q34181023-A1901A33-D674-4F38-84AF-A914D71E6F1B

P2860

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

http://www.wikidata.org/entity/Q33891844

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Genomic deletion of a long-ran ...... erostin in Van Buchem disease.

@ast

Genomic deletion of a long-ran ...... erostin in Van Buchem disease.

@en

type

label

Genomic deletion of a long-ran ...... erostin in Van Buchem disease.

@ast

Genomic deletion of a long-ran ...... erostin in Van Buchem disease.

@en

prefLabel

Genomic deletion of a long-ran ...... erostin in Van Buchem disease.

@ast

Genomic deletion of a long-ran ...... erostin in Van Buchem disease.

@en

P1433

Q33891844-78B78AFC-06B9-46A4-9E54-3BF0178B6D92

P1476

Q33891844-C52D8AAD-9BC4-4E22-9786-77A4F2743D91

P2093

Q33891844-502ADF82-27AC-455F-AE8A-88121A11ECD7

Q33891844-5CD1EF32-AE5E-4626-A0D2-A6DE17AA91D2

Q33891844-5D4B6DA9-690F-4611-BB22-D9D06360C6A4

Q33891844-68EC3BC0-7E33-4BF3-8CB5-96F896CB74AA

Q33891844-8BB5E270-B598-46AE-A444-921AD75B66B3

Q33891844-99EE02A3-5AF7-4EF0-8925-C96FBFAFB0F9

Q33891844-A673B9E5-9570-4534-A32D-BDEDF818AB6E

Q33891844-FA5A9901-A201-4FFF-93DF-ACE4A8C663CA

P2860

Q33891844-025EB19B-B199-4CC6-A9FF-B57395EEBD2A

Q33891844-03507A87-49CD-4CC7-A8F0-F35736F03E84

Q33891844-124889EF-C0C3-4330-B595-30C861B39839

Q33891844-2C2459B0-4E87-4265-AF25-685577DC8E2C

Q33891844-38FD893E-1F3A-4344-9E5E-4DA1A6374EFB

Q33891844-3D974DF5-865D-4ABA-B145-43C25BC03AEF

Q33891844-4977864F-4AFC-4F5C-9D48-59D14F507092

Q33891844-5196FF3E-841F-49AE-A529-7A276F199DA4

Q33891844-593124AC-3D06-48D0-B0DB-5B59FA6B22B3

Q33891844-5C639D7A-B259-4926-9DDD-DBC4BFE7262A

P304

Q33891844-ED264299-89AA-499B-AE39-23766DADE03E

P31

Q33891844-9A920050-AC5C-40CB-8336-FF205AE2F07E

P356

Q33891844-DB2709F4-D382-41BC-9632-1EED11B0405A

P433

Q33891844-C44DBD4A-5CEE-4264-81C2-B4F51606B329

P478

Q33891844-195DA2E2-790D-4497-A87F-62B016E31F58

P50

Q33891844-A821FAF6-2783-4F1F-8710-573A284350A9

P577

Q33891844-F3F08AD7-853B-477A-82D3-082F814E4B5A

P5875

Q33891844-5669D1D9-D63B-4AF0-9556-E26C635D43E4

P698

Q33891844-43B05A6C-1AA9-47E4-A809-1C8F4A60DA8F

P932

Q33891844-32CE243F-5642-4DAA-B7BE-060526C2AA3A

P356

P1433

Genome Research

P1476

Genomic deletion of a long-ran ...... erostin in Van Buchem disease.

@en

P2093

Dmitriy Ovcharenko

http://www.w3.org/2001/XMLSchema#string

Gabriela G Loots

http://www.w3.org/2001/XMLSchema#string

Hansjoerg Keller

http://www.w3.org/2001/XMLSchema#string

Ingrid Plajzer-Frick

http://www.w3.org/2001/XMLSchema#string

Jessie Chang

http://www.w3.org/2001/XMLSchema#string

Michaela Kneissel

http://www.w3.org/2001/XMLSchema#string

Myma Baptist

http://www.w3.org/2001/XMLSchema#string

Nicole M Collette

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites.

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

Novel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitis

A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly

Scanning human gene deserts for long-range enhancers

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

P304

928-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/GR.3437105

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Edward M. Rubin

P577

2005-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7778424

http://www.w3.org/2001/XMLSchema#string

P698

15965026

http://www.w3.org/2001/XMLSchema#string

P932

1172036

http://www.w3.org/2001/XMLSchema#string